One-two punch drug combination offers hope for pancreatic cancer therapy

November 18, 2019

LA JOLLA, CALIF. - Nov. 18, 2019 - Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice--supporting the immediate evaluation of the drugs in a clinical trial. U.S. Food and Drug Administration (FDA)-approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. The study was published in Nature Cell Biology.

"The sad reality is that at present, pancreatic cancer therapy is lagging since there is no effective treatment for these tumors," says Ze'ev Ronai, Ph.D., professor in Sanford Burnham Prebys' Tumor Initiation and Maintenance Program and senior author of the study. "Our study identifies a potential treatment combination that can immediately be tested against these aggressive tumors. We are already meeting with oncologists at Oregon Health & Science University to discuss how to advance this discovery into clinical evaluation."

Pancreatic cancer is one of the deadliest cancers. It is often difficult to diagnose because symptoms--such as pain in the abdomen, yellow skin and eyes, and weight loss--don't typically occur until the disease is advanced. Less than 10 percent of people with pancreatic cancer remain alive five years later. More than 56,000 Americans are expected to receive a pancreatic cancer diagnosis in 2019, according to the American Cancer Society.

In the study, the scientists used a drug called L-asparaginase to starve pancreatic tumors of a key nutrient, asparagine--an amino acid required for protein synthesis. Instead of dying, they found that the tumor turned on a stress response pathway that allowed the cancer cells to produce asparagine themselves. The scientists then treated mice with a second drug that blocked the stress response pathway and shrank the pancreatic tumor. L-asparaginase is FDA approved to treat certain leukemias; and the second drug, a MEK inhibitor, is approved for the treatment of solid tumors, including melanoma, a type of skin cancer.

"This research lays the basis for the inhibition of pancreatic tumor growth by a combined synergistic attack based on asparagine restriction and MAPK signaling inhibition," says Eytan Ruppin, M.D., Ph.D., a study author and chief of the Cancer Data Science Library at the National Cancer Institute, part of the National Institutes of Health (NIH). "Our lab was able to further support these findings through a computational analysis of patient data."

Adds Rosalie C. Sears, Ph.D., a professor at Oregon Health & Science University, "It's clear we're not going to find a single magic bullet that cures cancer but will instead need several drugs that target multiple vulnerabilities. This study identifies a promising dual treatment for pancreatic cancer--one of the deadliest cancers--and I look forward to seeing these drugs tested in patients."

In the same study, the scientists showed that the two treatments also shrank melanoma tumors in mice. Due to the large unmet clinical need in pancreatic cancer, the scientists have decided to focus on this cancer first.
The first author of the study is Gaurav Pathria, Ph.D., a senior postdoctoral associate in the Ronai lab. Additional study authors include Joo Sang Lee, Ph.D., of the NIH and Sungkyunkwan University of Medicine and Erez Hasnis, M.D., Ph.D., of Sanford Burnham Prebys, who contributed equally to the study; Kristofferson Tandoc of McGill University; David A. Scott, Ph.D., Sachin Verma, Ph.D., Yongmei Feng, Ph.D., of Sanford Burnham Prebys; Lionel Larue, Ph.D., of Institut Curie, University Paris-Sud and Equipe Labellisée Ligue Contre le Cancer; Avinash D. Sahu, Ph.D., of Harvard; Ivan Topisirovic, M.D., Ph.D., of Sungkyunkwan University of Medicine.

The study's DOI is 10.1038/s41556-019-0415-1.

Research reported in this press release was supported by the NIH (P30CA030199, R35CA197465, P01CA128814) and the Hevery Foundation.

About Sanford Burnham Prebys Medical Research Institute

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children's diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at or on Facebook at and on Twitter @SBPdiscovery.

Sanford Burnham Prebys Medical Discovery Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to